Could starting immunotherapy earlier improve outcomes for High-Risk melanoma?
NCT ID NCT07680699
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the two groups. No treatments are assigned by the study; all decisions are made by the patient's own doctor.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If early anti-PD-1 therapy proves beneficial, it could guide doctors on when to start treatment for high-risk melanoma.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by patient selection and cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CUTANEOUS MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Melanoma Trial: Vidutolimod + Nivolumab vs Nivol NCT04401995
- Melanoma SLNB Decision Aid Trial | NCT07653087
- Ultrasound Biomicroscopy for Melanoma Staging NCT04702854
- Study of Double-Positive Cells in Metastatic Can NCT06967961
- Melanoma Risk-Based Surgery Study for Kids | NCT07621614
- E7777 + Pembrolizumab for Ovarian Cancer (NCT05200559)
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AC Camargo Cancer Center
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••